Rebecca Araujo

DocwireNews

A meta-analysis published in <a href="https://www.frontiersin.org/articles/10.3389/fimmu.2023.1232244/full" target="_blank" rel="noopener">Frontiers of Immunology</a>&nbsp;found that for adults with lupus nephritis, a combination of tacrolimus (TAC), mycophenolate mofetil (MMF), and glucocorticoid (GC) demonstrated the greatest improvement in total remission rate compared with other combination immunosuppressive regimens.The researchers analyzed data from 62 randomized clinical trials, reported in 172 studies. A total of 6936 patients were included. Sample sizes ranged from 15 to 446 patients, and 37 of the trials were multicenter. Induction therapy was assessed in 44 trials, maintenance therapy was assessed in 7 trials, and the remaining 11 trials assessed both induction and maintenance. Follow-up ranged from 10.0 weeks to 92.4 months.The study population was treated with 20 categories of treatment regimens. The primary outcome was total remission rate. Secondary outcomes were complete remission, systemic lupus erythematosus disease activity index (SLEDAI), relapse, all-cause mortality, end-stage renal disease (ESRD), infection, herpes zoster, ovarian failure, myelosuppression, and cancer. Effects of treatment were compared and ranked using the surface under the cumulative ranking curve (SUCRA).<h2>Total, Complete Remission Rates</h2>Regarding the primary outcomes, the combination of TAC, MMF, and GC led to the greatest rate of total remission (SUCRA, 86.63%) compared with all other regimens. Ocrelizumab (OLB) plus GC showed the lowest total remission (SUCRA, 6.47%). The following regimens demonstrated a SUCRA for total remission &gt;70%:<ul>
<li>Azathioprine (AZA), cyclophosphamide (CYC), and GC (71.5%)</li>
<li>Abatacept (ABA), AZA, CYC, and GC (74.84%)</li>
<li>Belimumab (BLM), MMF/CYC, and GC (74.68%)</li>
<li>OLB, MMF, and GC (80.89%)</li>
<li>CYC, MMF/AZA/leflunomide (LEF), and GC (81.42%)</li>
<li>Voclosporin (VCS), MMF, and GC (85.05%)</li>
</ul>Compared with GC as a single agent, the odds ratios (ORs) for total remission were highest for the following regimens:<ul>
<li>ABA, AZA, CYC, and GC (OR, 6.89; 95% CI, 2.19-21.68)</li>
<li>AZA, CYC, and GC (OR, 6.82; 95% CI, 2.73-17.03)</li>
<li>BLM, MMF/CYC, and GC (OR, 7.04; 95% CI, 3.05-16.28)</li>
<li>CYC, MMF/AZA/LEF, and GC (OR, 7.72; 95% CI, 3.67-16.25)</li>
<li>Obinutuzumab (OTB), MMF, and GC (OR, 8.21; 95% CI, 3.54-19.08)</li>
<li>TAC, MMF, and GC (OR, 9.04, 95% CI, 5.13-15.92)</li>
<li>VCS, MMF, and GC (OR, 8.33; 95% CI, 4.76-14.56)</li>
</ul>The combination of VCS, MMF, and GC gave the best improvement in complete remission (SUCRA, 90.71%).<h2>Safety Outcomes</h2>The lowest risk of relapse was found for the combination of CYC, MMF, and GC (SUCRA, 85.57%); this combination was also associated with the lowest risk of cancer (SUCRA, 85.14%). OTB, MMF, and GC was associated with the lowest risk of all-cause mortality (SUCRA, 84.07%).Rituximab (RTX) plus MMF and GC demonstrated the greatest benefit regarding risk of ESRD (SUCRA, 83.11%). Risk of infection was lowest with AZA, CYC, and GC (SUCRA, 68.59%).In summary, the authors wrote, &ldquo;Our study found that TAC plus MMF plus GC provided the best therapeutic effect in terms of the total remission rate and SLEDAI.&rdquo; They added that &ldquo;MMF-based regimens, such as MMF plus CYC plus GC, OTB plus MMF plus GC, and RTX plus MMF plus GC, were optimal for preventing relapse, all-cause mortality, and ESRD.&rdquo;

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Assessing Lupus Nephritis Remission Rates After Use of Immunosuppressive Agent Combinations

Rheumatology

For adults with lupus nephritis, this treatment combo demonstrated the greatest improvement in total remission rate compared with other combination immunosuppressive regimens.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe